William Riley, Ph.D., Claudia S. Cohn, M.D., Ph.D., Kailey Love, M.B.A., M.S., and Jeffrey McCullough, M.D.
doi : 10.1056/NEJMp2302523
Vol. 388 No. 22
Anna T. Mayo, Ph.D., Christopher G. Myers, Ph.D., John C. Bucuvalas, M.D., Sandy Feng, M.D., Ph.D., and Courtney E. Juliano, M.D.
doi : 10.1056/NEJMp2300172
Wenjie Zi, M.D., Jiaxing Song, M.D., Weilin Kong, M.D., Jiacheng Huang, M.D., Changwei Guo, M.D., Wencheng He, M.D., Yinquan Yu, M.D., Bo Zhang, M.D., Wanjie Geng, M.D., Xiaolin Tan, M.D., Yaoyu Tian, M.D., Zongtao Liu, M.D.,
doi : 10.1056/NEJMoa2214299
The effects of the glycoprotein IIb/IIIa receptor inhibitor tirofiban in patients with acute ischemic stroke but who have no evidence of complete occlusion of large or medium-sized vessels have not been extensively studied.
Gregg W. Stone, M.D., William T. Abraham, M.D., JoAnn Lindenfeld, M.D., Saibal Kar, M.D., Paul A. Grayburn, M.D., D. Scott Lim, M.D., Jacob M. Mishell, M.D., Brian Whisenant, M.D., Michael Rinaldi, M.D., Samir R. Kapadia, M.D., Vivek Rajagopal, M.D., Ian J. Sarembock, M.B., Ch.B., M.D.,
doi : 10.1056/NEJMoa2300213
Data from a 5-year follow-up of outcomes after transcatheter edge-to-edge repair of severe mitral regurgitation, as compared with outcomes after maximal doses of guideline-directed medical therapy alone, in patients with heart failure are now available.
Peter J. Snelling, M.B., B.S., M.P.H.&T.M., Philip Jones, M.Biostat., David Bade, M.B., B.S., Randy Bindra, M.B., B.S., Joshua Byrnes, Ph.D., Michelle Davison, M.B., B.S., Shane George, M.P.H., Mark Moore, M.Nurs.N.P., Gerben Keijzers, Ph.D., and Robert S. Ware, Ph.D. for the BUCKLED Trial Group*
doi : 10.1056/NEJMoa2213883
Data on whether ultrasonography for the initial diagnostic imaging of forearm fractures in children and adolescents is noninferior to radiography for subsequent physical function of the arm are limited.
Nicholas C. Turner, M.D., Ph.D., Mafalda Oliveira, M.D., Ph.D., Sacha J. Howell, M.D., Ph.D., Florence Dalenc, M.D., Ph.D., Javier Cortes, M.D., Ph.D., Henry L. Gomez Moreno, M.D., Ph.D., Xichun Hu, M.D., Komal Jhaveri, M.D., Petr Krivorotko, M.D., Ph.D., Sibylle Loibl, M.D., Ph.D., Serafin Morales Murillo, M.D., Meena Okera, M.D., Yeon Hee Park, M.D., Ph.D., Joohyuk Sohn, M.D., Masakazu Toi, M.D., Ph.D., Eriko Tokunaga, M.D., Ph.D., Samih Yousef, M.D., Lyudmila Zhukova, M.D., Ph.D., Elza C. de Bruin, Ph.D., Lynda Grinsted, M.Sc., Gaia Schiavon, M.D., Ph.D., Andrew Foxley, M.F.P.M., and Hope S. Rugo, M.D. for the CAPItello-291 Study Group*
doi : 10.1056/NEJMoa2214131
AKT pathway activation is implicated in endocrine-therapy resistance. Data on the efficacy and safety of the AKT inhibitor capivasertib, as an addition to fulvestrant therapy, in patients with hormone receptor–positive advanced breast cancer are limited.
Anna Santoro, Pharm.D., Ph.D., and Barbara B. Kahn, M.D.
doi : 10.1056/NEJMra2216691
Enrique M. Baldessari, M.D., and Sara M. Mesquida, M.D.
doi : 10.1056/NEJMicm2214264
Debasish Biswal, M.D., and Bijay Mirdha, M.D.
doi : 10.1056/NEJMicm2211056
Michael S. Bohnen, M.D., Ph.D., Brahmajee K. Nallamothu, M.D., M.P.H., Robert Zilinyi, M.D., Sanjay Saint, M.D., M.P.H., and Emily D. Slater, M.D.
doi : 10.1056/NEJMcps2215388
Jose G. Romano, M.D., and Tatjana Rundek, M.D., Ph.D.
doi : 10.1056/NEJMe2303184
John J.V. McMurray, M.D., and Marco Metra, M.D.
doi : 10.1056/NEJMe2302924
doi : 10.1056/NEJMc2300561
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟